NCT03834961: Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: NTRK
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: up to 30 Years (Child, Adult)
Location of Metastases: 
Additional Notes: Patients must have an NTRK1, NTRK2, or NTRK3 fusion; Breast cancer patients will be assigned to cohort B
Exclusions: Patients with prior anti-cancer therapy, including radiotherapy; Surgical resection is permitted

Comments are closed.

Up ↑